MedTrace Logo

Biomarker Study Accompanying the AIO-TRK-0114 Study (MARBLE)

NCT02595840 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2019-04-19

No results posted yet for this study

Summary

To compare the efficacy of afatinib maintenance with pemetrexed maintenance following induction therapy with platinum/ pemetrexed in patients with metastatic EGFR mutated non-small-cell lung cancer progressing after first-line treatment with afatinib as first tyrosine kinase inhibitor with respect to progression-free survival

Conditions

  • Non-small-cell Lung Cancer With Somatic EGFR Mutations

Interventions

DRUG

Afatinib

DRUG

Pemetrexed

Sponsors & Collaborators

  • Universität Duisburg-Essen

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-25
Primary Completion
2017-11-20
Completion
2017-11-20

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02595840 on ClinicalTrials.gov